Lyn-IN-1, an analog of Bafetinib, is a potent and selective dual kinase inhibitor targeting both Bcr-Abl and Lyn. It is utilized in biochemical and cellular research, particularly in studies of chronic myeloid leukemia (CML), demonstrating activity in both in vitro assays and in vivo models.
